Research Center for Evidence-Based Medicine, Iranian EBM Centre: JBI Centre of Excellence, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Urology Department, Iran University of Medical Sciences, Tehran, Iran.
Urol J. 2024 Jun 9;21(4):208-220. doi: 10.22037/uj.v20i.8036.
The quantitative objective of the current systematic review was to identify the potential role of urinary microbiota in bladder cancer (BC) carcinogenesis, invasiveness, progression, and metastasis.
The proposed systematic review was conducted in accordance with critical review according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement, and the Joanna Briggs Institute (JBI) methodology for systematic reviews. The search strategy aimed to find both published and unpublished studies up to the January 2024. A JBI appraisal checklist was used to assess possible biases.
This systematic review was centered on 27 studies comprising 926 BC patients. Overall, 412 control individuals were compared with BC patients. The most common sampling method was midstream urine collection. Regarding microbial alpha diversity, there was no statistically significant difference between cancerous and healthy samples (n = 8), recurrent and not recurrent (n = 1), responders versus non-responders(n = 1), tumor grades (n = 1), and collection methods (n = 1). However, five studies reported higher diversity in controls, and five other studies reported, conversely, high levels of alpha diversity in BC patients or recurrent cases. Furthermore, a responder (RE) to treatment and a non-muscle invasive bladder cancer (NMIBC) groups demonstrated significant difference with non-responder (NR) and muscle invasive bladder cancer (MIBC), respectively. In terms of beta-diversity, nine studies reported significant diversity between BC patients and controls, one article demonstrated difference between recurrent and not recurrent patients, a study reported significant difference in RE and NR groups whereas another showed opposite, and others (n = 4) did not find any difference between BC, controls, MIBC and NMIBC patients, or between tumor grades. One study reported a difference between the collection method and beta-diversity in males and another reported the difference in females.
The included studies demonstrate that the composition of urinary microbiota is altered in patients with BC. However, the differentially enriched genera in the urine of these patients vary between studies, and there is too much heterogeneity across studies to make any reliable and valid conclusions. Furthermore, well-designed research is necessary to assess the role of microbiota in the carcinogenesis and progression of BC.
本系统评价的定量目的是确定尿微生物组在膀胱癌(BC)发生、侵袭、进展和转移中的潜在作用。
本系统评价是按照循证医学系统评价的首选报告项目(PRISMA)声明和乔安娜·布里格斯研究所(JBI)系统评价方法进行的。搜索策略旨在找到截至 2024 年 1 月的已发表和未发表的研究。使用 JBI 评估检查表评估可能存在的偏倚。
本系统评价集中于 27 项研究,共纳入 926 例 BC 患者。总体上,将 412 名对照个体与 BC 患者进行比较。最常见的采样方法是中段尿采集。关于微生物 alpha 多样性,癌症和健康样本之间(n=8)、复发和非复发样本之间(n=1)、应答者与非应答者之间(n=1)、肿瘤分级之间(n=1)和采集方法之间(n=1)均无统计学差异。然而,有 5 项研究报告说对照组的多样性更高,有 5 项其他研究报告说,BC 患者或复发病例的 alpha 多样性较高。此外,治疗应答者(RE)和非肌肉浸润性膀胱癌(NMIBC)组与非应答者(NR)和肌肉浸润性膀胱癌(MIBC)组之间存在显著差异。关于 beta 多样性,9 项研究报告说 BC 患者和对照组之间存在显著差异,1 项研究报告说复发和非复发患者之间存在差异,1 项研究报告说 RE 和 NR 组之间存在显著差异,而另一项研究报告说相反,还有其他 4 项研究没有发现 BC、对照组、MIBC 和 NMIBC 患者之间或肿瘤分级之间存在任何差异。一项研究报告说,收集方法和男性尿液中的 beta 多样性之间存在差异,另一项研究报告说,女性之间存在差异。
纳入的研究表明,BC 患者尿液中的微生物组成发生了改变。然而,这些患者尿液中差异丰富的属在不同研究之间存在差异,而且研究之间存在太多异质性,无法得出任何可靠和有效的结论。此外,需要进行精心设计的研究来评估微生物在 BC 发生和进展中的作用。